For all its bluster about the various attractions of emerging markets, pharma’s foray into them has thus far been decidedly one dimensional. Multinationals’ current focus on tapping into new territories to juice top-line growth is understandable, especially given the severity of the business challenges on its home turf and the vast potential opportunities in core developing countries. Their efforts to harness innovation in emerging markets, whether scientific or strategic, have been less forceful, however, and remain largely a longer-term goal.
Yet, how Big Pharma perceives and accesses innovation in emerging markets is critically important to its welfare. Emerging markets offer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?